Table 1.

Study characteristics of trials meeting inclusion in the systematic review.

Authors	Country of study	Patients	Cycle Type	Ovarian stimulation	Progesterone Type	Randomization Groups (by initiation of P)	P regimen	Ovulation triggering
Sohn et al. 1999	USA	General IVF-no exclusion reported	Fresh augolous IVF	Long GnRH agonist with hMG and/or FSH.	Progesterone 12.5 mg IM then 25mg IM Progesterone 25 mg IM	Group A: 12.5mg dose 12 hours before OR and the evening of OR then 25mg dose Group B: evening of OR	Daily through first trimester	hCG (amount not stated)
Williams et al. 2001	USA	General IVF-no exclusion reported	Fresh augolous IVF	Long GnRH agonist, luteal GnRH agonist stop, or GnRH agonist micro-dose flare. rFSH 150–450 IU daily.	Prometrium, 200mg vaginally TID	Group A: morning of the 3rd day after OR Group B: morning of the 6th day after OR	Daily until 10 weeks gestation	10,000 units hCG
Fanchin et al. 2001	France	General IVF-excluded patients with abnormal uterus	Fresh augolous IVF	Long GnRH agonist. rFSH 225 IU FSH for 5 days, then flexible dosing	Crinone 8% vaginally	Group A: immediately after OR Group B: evening of ET	Daily until pregnancy ruled out	10,000 units hCG
Baruffi et al. 2003	Brazil	General IVF-no exclusion reported	Fresh augolous IVF	Long GnRH agonist. rFSH 150–300 IU daily.	Utrogestan, 400 mg vaginally	Group A: evening of ORGroup B: evening of ET	Not stated	5,000-10,000 units hCG
Mochtar et al. 2006	Netherlands	General IVF-no exclusion reported	Fresh augolous IVF	Long GnRH agonist. rFSH, hMG, or hpFSH.	Micronized progesterone 400 mg vaginally BID	Group A: evening of hCG administration Group B: evening after OR Group C: evening 3 days after OR	Daily until 18 days post OR	10,000 units hCG